Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pulmonary arterial hypertension: an overview.

James R Klinger1

  • 1Division of Pulmonary, Sleep and Critical Care Medicine, Rhode Island Hospital, Brown Medical School, Providence, Rhode Island 02903, USA. james_klinger@brown.edu

Seminars in Cardiothoracic and Vascular Anesthesia
|May 31, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of drug candidates for rescue of SOX17 gene targets in pulmonary arterial hypertension.

bioRxiv : the preprint server for biology·2026
Same author

Impaired SOX17 Expression Causes Endothelial Dysfunction and Pulmonary Arterial Hypertension by Insufficient Suppression of RUNX1.

bioRxiv : the preprint server for biology·2026
Same author

Evolving Concepts in Pulmonary Hypertension: Implementation Challenges of the Current Guidelines and Proceedings in the US.

Chest·2026
Same author

Exploring the Lung-Liver Axis in Pulmonary Arterial Hypertension.

Comprehensive Physiology·2026
Same author

Individualized Interactomes from Pulmonary Arterial Hypertension Cell Biopsies Predict Therapeutic Response.

medRxiv : the preprint server for health sciences·2025
Same author

The Liver is an Inflammatory Mediator of Pulmonary Arterial Hypertension.

bioRxiv : the preprint server for biology·2025
Same journal

Alpha-Gal Syndrome-A Case Series of Successful Transcatheter Mammalian-Derived Aortic Valve Replacements.

Seminars in cardiothoracic and vascular anesthesia·2026
Same journal

Vasopressor Selection and Postoperative Delirium in Older Adults: A Propensity-Matched Database Analysis.

Seminars in cardiothoracic and vascular anesthesia·2026
Same journal

Letter to the Editor: A Scalable Alternative to In Vitro Contracture Testing for Incidentally Discovered Genetic Variants for Malignant Hyperthermia.

Seminars in cardiothoracic and vascular anesthesia·2026
Same journal

Variations in Intraoperative Opioid Use in Cardiac Surgical Patients With Midline Sternotomy.

Seminars in cardiothoracic and vascular anesthesia·2026
Same journal

Statistics for the Clinician II: The T-test, Its Versions, and Its Alternatives.

Seminars in cardiothoracic and vascular anesthesia·2026
Same journal

Abdominal Organ Transplantation: Noteworthy Literature in 2025.

Seminars in cardiothoracic and vascular anesthesia·2026
See all related articles

Pulmonary arterial hypertension (PAH) research has advanced, improving therapies and survival. Understanding PAH pathogenesis and classification remains key for future treatments.

Area of Science:

  • Cardiology
  • Pulmonology
  • Medical Genetics

Background:

  • Pulmonary arterial hypertension (PAH) has been known for over a century, yet its underlying mechanisms and cures are not fully understood.
  • Despite being rare, PAH affects all age groups and is linked to various unrelated conditions, raising questions about its unified pathology.
  • Recent classification efforts aid in organizing data from registries and trials, facilitating research progress.

Purpose of the Study:

  • To provide an overview of the history, epidemiology, and genetic underpinnings of Pulmonary arterial hypertension (PAH).
  • To discuss updated recommendations for classifying different forms of PAH.
  • To identify prognostic variables impacting patient survival in PAH.

Main Methods:

  • Literature review and synthesis of historical data.

Related Experiment Videos

  • Analysis of recent classification guidelines for pulmonary hypertension.
  • Examination of prognostic factors from clinical studies and patient registries.

    • Main Results:

    • Significant advancements in understanding PAH pathogenesis and development of new therapies.
    • Improved patient function and survival rates due to recent therapeutic interventions.
    • Ongoing challenges in definitively classifying PAH and understanding its diverse etiologies.

    Conclusions:

    • Despite progress, a complete understanding of PAH pathogenesis and a definitive cure remain elusive.
    • Current classification systems help organize research but do not fully resolve the heterogeneity of PAH.
    • Identifying adverse prognostic variables is crucial for improving long-term outcomes in Pulmonary arterial hypertension patients.